Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 2/20 | 0.42 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.42 |
| ▸ | TPH1 | P17752 | 2/20 | 0.37 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.36 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.36 |
| ▸ | LTB4R | Q15722 | 4/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.35 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.35 |
| ▸ | HSD17B1 | P14061 | 4/20 | 0.35 |
| ▸ | HSD17B2 | P37059 | 4/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | CLK1 | P49759 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.34 |
| ▸ | CASR | P41180 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25652897 | 0.92 | HSD17B1 (0.41) | TPH1LTB4RHSD17B1HSD17B2CNR2 | |
| SCHEMBL25652737 | 0.88 | HSD17B1 (0.46) | TPH1LTB4RHSD17B1HSD17B2CNR2 | |
| SCHEMBL25652871 | 0.86 | ACMSD (0.38) | CYP4F2CYP4A11LTB4RCNR2ACMSD | |
| SCHEMBL25652807 | 0.86 | ACMSD (0.38) | CYP4F2CYP4A11LTB4RCNR2ACMSD | |
| SCHEMBL25652870 | 0.84 | ACMSD (0.36) | CYP4F2CYP4A11LTB4RCNR2ACMSD | |
| SCHEMBL25653073 | 0.82 | HSD17B1 (0.39) | TPH1LTB4RHSD17B1HSD17B2 | |
| SCHEMBL25653074 | 0.80 | LTB4R (0.36) | TPH1LTB4RHSD17B1HSD17B2 | |
| SCHEMBL26564975 | 0.78 | CNR2 (0.43) | LTB4RHSD17B1HSD17B2CNR2ACMSD | |
| SCHEMBL25652750 | 0.78 | CNR2 (0.43) | LTB4RHSD17B1HSD17B2CNR2ACMSD | |
| SCHEMBL25652551 | 0.77 | L3MBTL1 (0.46) | CYP4F2CYP4A11LTB4RACMSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12018011-B2 | Macrocyclic compounds and compositions, and methods of preparing and using the same | KURA ONCOLOGY, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-20230322711-A1 | MACROCYCLIC COMPOUNDS AND COMPOSITIONS, AND METHODS OF PREPARING AND USING THE SAME | WUXI APPTEC (HONG KONG) LIMITED (CN) | 2023-10-12 | — | — | US | disclosed |
| US-20230322711-A1 | MACROCYCLIC COMPOUNDS AND COMPOSITIONS, AND METHODS OF PREPARING AND USING THE SAME | WUXI APPTEC (HONG KONG) LIMITED (CN) | 2023-10-12 | — | — | US | disclosed |
| WO-2023102378-A1 | MACROCYCLIC COMPOUNDS HAVING FARNESYLTRANSFERASE INHIBITORY ACTIVITY | KURA ONCOLOGY, INC. (US) | 2023-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12018011-B2 | Macrocyclic compounds and compositions, and methods of preparing and using the same | FNTA, FDPS, GGPS1 | CYP4F2 96/4885CYP4A11 61/4885TPH1 4766/4885 |
| US-20230322711-A1 | MACROCYCLIC COMPOUNDS AND COMPOSITIONS, AND METHODS OF PREPARING AND USING THE SAME | FNTA, FDPS, GGPS1 | CYP4F2 96/4885CYP4A11 61/4885TPH1 4766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.